Pharma GxP Audit & Deviation Management Agent
XenonStack · Intelligence & Research
Certification per Microsoft Marketplace.
Evidence tier Source Confirmed · 7 captures on record
What the publisher says
As described on Microsoft Marketplace.
Overview
ElixirClaw (Enterprise Agentic OS) enables pharmaceutical organizations to autonomously orchestrate deviation investigations, CAPA workflows, audit readiness, and GxP compliance operations through governed AI agents.
Show the rest of the publisher’s description (26 more lines)
The platform continuously evaluates quality events, operational deviations, inspection evidence, and corrective actions while enforcing strict human-in-the-loop governance for regulatory and compliance-critical workflows.
Key Benefits
- Automated deviation investigation and root-cause orchestration
- Faster CAPA initiation, tracking, and closure workflows
- Continuous audit readiness and inspection evidence assembly
- Governed approval workflows for regulatory submissions
- Reduced manual effort across quality and compliance teams
- Full traceability for every compliance and remediation actionHow It Works
ElixirClaw integrates with QMS platforms, laboratory systems, MES environments, document repositories, ERP systems, and compliance workflows.
The agent continuously monitors deviations, quality incidents, CAPA status, audit readiness signals, and regulatory requirements. Based on predefined governance policies, it orchestrates investigation workflows, corrective actions, evidence assembly, and audit preparation activities.
All regulatory filing, CAPA closure, and compliance-critical actions pass through governance gates. Human approval is enforced before submission, escalation, or regulatory communication.
Every workflow generates a Decision Trace capturing evidence sources, investigation steps, approvals, CAPA actions, and compliance execution history.
Business Impact
- Reduced deviation investigation cycle times
- Faster CAPA execution and remediation workflows
- Improved audit preparedness and inspection response
- Reduced operational burden on quality and compliance teams
- Increased consistency in GxP compliance operations
- Enhanced traceability across regulated quality processesIdeal For
- Pharmaceutical and life sciences organizations
- VP Quality and GxP governance teams
- Regulatory affairs and inspection readiness functions
- Compliance teams managing CAPA and audit workflowsIndustries
- Pharmaceuticals
- Life Sciences
- Regulated Manufacturing
Preview
3 images
Agent build and provenance
See the full provenance
The layer-by-layer build, the evidence behind each claim, the risk basis and the cross-marketplace links are open to any account. Some rows are disclosed, some the source leaves Unknown; a free account shows you which.
Compliance
- FedRAMPConfirmedNot listed90%, registry-checkedNo FedRAMP Marketplace entry matched this vendor's domain, checked 2026-08-27registry recordas observed 2026-08-27
Confirmed means matched to a public authoritative registry. Claimed means the vendor or its listing states it, not yet cross-checked. A framework not shown was not found in any source we hold, which is not evidence against it. Not listed means a scoped registry check found no match for this vendor's domain: a No is a scoped registry check, not a compliance judgment. Confidence bands: 95% domain-verified, 90% registry-checked, 80% self-attested, 70% weak signal. Self-attested items marked “vendor's site” are gathered from the vendor's own website and are not verified by us.
Vendor
External enrichment · as of 2026-08-29
Sources
Publisher resources
8 linksLinked repositories
Unknown means this listing does not publish a repository. It is not a statement that the code is closed, and a linked repository is not a claim that the publisher wrote it: the registry computes that relationship privately and does not publish it.
Evidence risk is the share of the build you cannot see before you deploy, not a security rating. Sign in to see the layer-by-layer basis for this band.